The Medicamen Organics IPO share allotment will be finalized today, Wednesday, June 26. Investors who applied for this IPO can check their allotment status on the registrar’s website, Kfin Technologies Ltd. The IPO opened for subscription on Friday, June 21, and closed on Tuesday, June 25. On the last day of bidding, the subscription status was 993.56 times.
How to Check Allotment Status:
- Visit the Kfin Technologies website: IPO Allotment Link
- Select IPO: Choose “Medicamen Organics IPO” from the drop-down menu.
- Choose Your Details: Select either Application No., Demat Account, or PAN to check the status.
- Enter Required Information:
- If you choose the application number, enter it along with the captcha code and click “Submit.”
- If you select Demat Account, enter your account details and captcha code, then click “Submit.”
- For PAN, enter your PAN number and captcha, then click “Submit.”
Allotment and Refund Process:
- Investors will find out how many shares they have been allotted. Those who did not receive shares will start getting refunds from Thursday, June 27.
- Allotted shares will be credited to investors’ demat accounts on the same day.
- The IPO is scheduled to list on Friday, June 28.
Medicamen Organics IPO GMP:
The grey market premium (GMP) for Medicamen Organics IPO is +50, indicating that shares are trading at a ₹50 premium in the grey market. Given the upper IPO price band and current GMP, the expected listing price is ₹84 per share, which is 147.06% higher than the IPO price of ₹34.
GMP Trends:
For the past 13 sessions, the GMP has been trending upward, suggesting a strong listing. Analysts at investorgain.com have observed that the GMP has ranged from ₹17 to ₹60.
Note: The grey market premium reflects investors’ willingness to pay more than the issue price.
Disclaimer: The views and investment tips expressed by investment experts on Sharepriceindia.com are their own and not those of the website or its management. Sharepriceindia.com advises users to check with certified experts before taking any investment decisions.